Comparison of Efficacy on Healing, and Safety of Two Dressings Urgotul and TulleGras MS on Surgical Acute Wounds.

Multicentre, Randomized, Parallel Group, Non-inferiority, Open-label Study Aiming at Comparing the Healing Rates (With Blinded Assessment Based on Photographs) of TULLEGRAS M.S.® With URGOTUL® in the Treatment of Surgical Acute Wounds.

Evaluation of non-inferiority on healing rates of two dressings Urgotul and TulleGras MS in the treatment of surgical acute wounds.

Inclusion Criteria:

• Male or female subject.
• Aged 18 to 75 years
• With a planned surgery:
• Of abdominal location
• Leading to an acute wound of a maximum total length ≤ 18 cm (corresponding to 2 investigational products)
• Absence of clinical sign suggestive of worsened wound (assessed only at the randomization visit)
• Followed-up in surgery department
• Written and signed informed consent obtained
• Affiliated to the French Social Security system or equivalent.

Exclusion Criteria:

• Underlying pathology that may interfere with wound healing in the opinion of the Investigator (human immunodeficiency virus [HIV], cancer, immunodeficiency disease, generalized infection, systemic disease ...). The presence of low-risk prostate cancer according to the Amico classification (1) (PSA<10 ng/mL and Gleason's score < 6 and clinical grade T1c ou T2a) or a grade T1 (a or b) N0M0 renal cancer which requires surgery without adjuvant therapy (radiotherapy, chemotherapy, hormonal therapy...), in a patient whose general condition is preserved without significant comorbidity or signs of malnutrition are not considered as a non- inclusion criteria
• Inadequately controlled diabetes (Glycosylated hemoglobin > 8%)
• Hypo or hyperthyroidism
• Intake of a systemic treatment with glucocorticoids or immunosuppressives
• Known allergy to one of study dressings components
• Participation in a clinical trial in the month prior to his/her inclusion in the study
• Pregnancy or breastfeeding or of childbearing potential and saying not to use contraception.